Top

Published in:

01-07-2016 | Original Article

Biological characteristics of a novel giant cell tumor cell line derived from spine

Authors: Zhenhua Zhou, Yan Li, Leqin Xu, Xudong Wang, Su Chen, Cheng Yang, Jianru Xiao

Published in: Tumor Biology | Issue 7/2016

Abstract

Giant cell tumor of bone(GCTB) is a special bone tumor for it consists of various cell types, and its biological characteristics is different from common benign or malignant neoplasm. In the present study, we report the biological features of a primary Asian GCTB cell line named GCTB28. We analyzed extensive properties of the GCTB28 cells including morphological observations, growth, cell cycle, karyotype, proliferation, proteins expression, surface biomarker verification, and tumorigenicity in nude mice. We found that the stromal cells of GCTB were endowed with self-renewal capacity and played dominant roles in GCTB development. Moreover, we confirmed that GCTB cells can be CD33⁻CD14⁻ phenotype which was not in accord with previous study. This study provides an in vitro model system to investigate pathogenic mechanisms and molecular characteristics of GCTB and also provides a useful tool for researching the therapeutic targeting of GCTB.

Available only for authorised users

Bhurgri Y, Usman A, Bhurgri H, Faridi N, Bashir I, Bhurgri A, et al. Primary malignancies of bone and cartilage in Karachi. Asian Pac J Cancer Prev : APJCP. 2009;10(5):891–4.PubMed

Saikia KC, Bhuyan SK, Borgohain M, Saikia SP, Bora A, Ahmed F. Giant cell tumour of bone: an analysis of 139 Indian patients. J Orthop Sci : Off J Jpn Orthop Assoc. 2011;16(5):581–8. doi:10.1007/s00776-011-0033-7.CrossRef

Puri A, Agarwal MG, Shah M, Jambhekar NA, Anchan C, Behle S. Giant cell tumor of bone in children and adolescents. J Pediatr Orthop. 2007;27(6):635–9. doi:10.1097/BPO.0b013e3181425629.CrossRefPubMed

Rajani R, Schaefer L, Scarborough MT, Gibbs CP. Giant cell tumors of the foot and ankle bones: high recurrence rates after surgical treatment. J Foot Ankle Surg : Off Publ Am Coll Foot Ankle Surg. 2014. doi:10.1053/j.jfas.2014.08.016.

Abat F, Almenara M, Peiro A, Trullols L, Bague S, Gracia I. Giant cell tumour of bone: a series of 97 cases with a mean follow-up of 12 years. Revista espanola de cirugia ortopedica y traumatologia. 2015;59(1):59–65. doi:10.1016/j.recot.2014.06.005.CrossRefPubMed

Shen CC, Li H, Shi ZL, Tao HM, Yang ZM. Current treatment of sacral giant cell tumour of bone: a review. J Int Med Res. 2012;40(2):415–25.CrossRefPubMed

Huang TS, Green AD, Beattie CW, Das Gupta TK. Monocyte-macrophage lineage of giant cell tumor of bone. Establishment of a multinucleated cell line. Cancer. 1993;71(5):1751–60.CrossRefPubMed

Kito M, Moriya H, Mikata A, Harigaya K, Takenouchi T, Takada N, et al. Establishment of a cell line from a human giant cell tumor of bone. Clin Orthop Relat Res. 1993;294:353–60.

Werner M. Giant cell tumour of bone: morphological, biological and histogenetical aspects. Int Orthop. 2006;30(6):484–9. doi:10.1007/s00264-006-0215-7.CrossRefPubMedPubMedCentral

10.

Chakarun CJ, Forrester DM, Gottsegen CJ, Patel DB, White EA, Matcuk Jr GR. Giant cell tumor of bone: review, mimics, and new developments in treatment. Radiographics : Rev Publ Radiol Soc North Am Inc. 2013;33(1):197–211. doi:10.1148/rg.331125089.CrossRef

11.

Raskin KA, Schwab JH, Mankin HJ, Springfield DS, Hornicek FJ. Giant cell tumor of bone. J Am Acad Orthop Surg. 2013;21(2):118–26. doi:10.5435/jaaos-21-02-118.CrossRefPubMed

12.

Cowan RW, Singh G. Giant cell tumor of bone: a basic science perspective. Bone. 2013;52(1):238–46. doi:10.1016/j.bone.2012.10.002.CrossRefPubMed

13.

Yeo CD, Roh SY, Shin OR, Bahk WJ, Kim KH, Kim JW. A case of pulmonary metastasis of giant cell tumor of bone presenting as pulmonary arteriovenous malformation. J Formos Med Assoc = Taiwan yi zhi. 2015;114(4):369–72. doi:10.1016/j.jfma.2012.03.014.CrossRefPubMed

14.

Chan CM, Adler Z, Reith JD, Gibbs Jr CP. Risk factors for pulmonary metastases from giant cell tumor of bone. J Bone Joint Surg Am Vol. 2015;97(5):420–8. doi:10.2106/jbjs.n.00678.CrossRef

15.

Goldenberg RR, Campbell CJ, Bonfiglio M. Giant-cell tumor of bone. An analysis of two hundred and eighteen cases. J Bone Joint Surg Am Vol. 1970;52(4):619–64.CrossRef

16.

Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-cell tumor of bone. J Bone Joint Surg Am Vol. 1987;69(1):106–14.CrossRef

17.

Goldring SR, Roelke MS, Petrison KK, Bhan AK. Human giant cell tumors of bone identification and characterization of cell types. J Clin Invest. 1987;79(2):483–91. doi:10.1172/jci112838.CrossRefPubMedPubMedCentral

18.

Song ZB, Ni JS, Wu P, Bao YL, Liu T, Li M, et al. Testes-specific protease 50 promotes cell invasion and metastasis by increasing NF-kappaB-dependent matrix metalloproteinase-9 expression. Cell Death Dis. 2015;6:e1703. doi:10.1038/cddis.2015.61.CrossRefPubMedPubMedCentral

19.

Akter H, Park M, Kwon OS, Song EJ, Park WS, Kang MJ. Activation of matrix metalloproteinase-9 (MMP-9) by neurotensin promotes cell invasion and migration through ERK pathway in gastric cancer. Tumour Biol : J Int Soc Oncodev Biol Med. 2015. doi:10.1007/s13277-015-3282-9.

20.

Liu Y, Liu H, Luo X, Deng J, Pan Y, Liang H. Overexpression of SMYD3 and matrix metalloproteinase-9 are associated with poor prognosis of patients with gastric cancer. Tumour Biol : J Int Soc Oncodev Biol Med. 2015. doi:10.1007/s13277-015-3077-z.

21.

Tamamura R, Nagatsuka H, Siar CH, Katase N, Naito I, Sado Y, et al. Comparative analysis of basal lamina type IV collagen alpha chains, matrix metalloproteinases-2 and -9 expressions in oral dysplasia and invasive carcinoma. Acta Histochem. 2013;115(2):113–9. doi:10.1016/j.acthis.2012.05.001.CrossRefPubMed

22.

Xia Z, Liu W, Li S, Jia G, Zhang Y, Li C, et al. Expression of matrix metalloproteinase-9, type IV collagen and vascular endothelial growth factor in adamantinous craniopharyngioma. Neurochem Res. 2011;36(12):2346–51. doi:10.1007/s11064-011-0560-9.CrossRefPubMed

23.

Cao XL, Xu RJ, Zheng YY, Liu J, Teng YS, Li Y, et al. Expression of type IV collagen, metalloproteinase-2, metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in laryngeal squamous cell carcinomas. Asian Pac J Cancer Prev : APJCP. 2011;12(12):3245–9.PubMed

24.

Xu XH, Pan W, Kang LH, Feng H, Song YQ. Association of annexin A2 with cancer development (Review). Oncol Rep. 2015;33(5):2121–8. doi:10.3892/or.2015.3837.PubMed

25.

Wang CY, Lin CF. Annexin A2: its molecular regulation and cellular expression in cancer development. Dis Markers. 2014;2014:308976. doi:10.1155/2014/308976.PubMedPubMedCentral

26.

Sharma MC, Sharma M. The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target. Curr Pharm Des. 2007;13(35):3568–75.CrossRefPubMed

27.

Liu X, Ma D, Jing X, Wang B, Yang W, Qiu W. Overexpression of ANXA2 predicts adverse outcomes of patients with malignant tumors: a systematic review and meta-analysis. Med Oncol (Northwood, London, England). 2015;32(1):392. doi:10.1007/s12032-014-0392-y.CrossRef

28.

Leal MF, Calcagno DQ, Chung J, de Freitas VM, Demachki S, Assumpcao PP, et al. Deregulated expression of annexin-A2 and galectin-3 is associated with metastasis in gastric cancer patients. Clin Exp Med. 2014. doi:10.1007/s10238-014-0299-0.

29.

Ma RL, Shen LY, Chen KN. Coexpression of ANXA2, SOD2 and HOXA13 predicts poor prognosis of esophageal squamous cell carcinoma. Oncol Rep. 2014;31(5):2157–64. doi:10.3892/or.2014.3088.PubMed

30.

Zhai H, Acharya S, Gravanis I, Mehmood S, Seidman RJ, Shroyer KR, et al. Annexin A2 promotes glioma cell invasion and tumor progression. J Neurosci : Off J Soc Neurosci. 2011;31(40):14346–60. doi:10.1523/jneurosci.3299-11.2011.CrossRef

31.

Zhang W, Zhao P, Xu XL, Cai L, Song ZS, Cao DY, et al. Annexin A2 promotes the migration and invasion of human hepatocellular carcinoma cells in vitro by regulating the shedding of CD147-harboring microvesicles from tumor cells. PLoS One. 2013;8(8):e67268. doi:10.1371/journal.pone.0067268.CrossRefPubMedPubMedCentral

32.

Deng S, Jing B, Xing T, Hou L, Yang Z. Overexpression of annexin A2 is associated with abnormal ubiquitination in breast cancer. Genomics Proteomics Bioinformatics. 2012;10(3):153–7. doi:10.1016/j.gpb.2011.12.001.CrossRefPubMedPubMedCentral

33.

Yang J, Yang F, Nie J, Zou X, Tian H, Qin Y, et al. Evaluation of Annexin A2 as a novel diagnostic serum biomarker for lung cancer. Cancer Biomark : Section A Dis Markers. 2015;15(2):211–7. doi:10.3233/cbm-140455.CrossRef

34.

Emoto K, Yamada Y, Sawada H, Fujimoto H, Ueno M, Takayama T, et al. Annexin II overexpression correlates with stromal tenascin-C overexpression: a prognostic marker in colorectal carcinoma. Cancer. 2001;92(6):1419–26.CrossRefPubMed

35.

Liu Y, Wang Z, Jiang M, Dai L, Zhang W, Wu D, et al. The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia. Leuk Res. 2011;35(7):879–84. doi:10.1016/j.leukres.2010.11.008.CrossRefPubMed

36.

Huang YK, Liu H, Wang XZ, Zhu S. Annexin A2 and CD105 expression in pancreatic ductal adenocarcinoma is associated with tumor recurrence and prognosis. Asian Pac J Cancer Prev : APJCP. 2014;15(22):9921–6.CrossRefPubMed

37.

Ohno Y, Izumi M, Kawamura T, Nishimura T, Mukai K, Tachibana M. Annexin II represents metastatic potential in clear-cell renal cell carcinoma. Br J Cancer. 2009;101(2):287–94. doi:10.1038/sj.bjc.6605128.CrossRefPubMedPubMedCentral

38.

Das S, Shetty P, Valapala M, Dasgupta S, Gryczynski Z, Vishwanatha JK. Signal transducer and activator of transcription 6 (STAT6) is a novel interactor of annexin A2 in prostate cancer cells. Biochemistry. 2010;49(10):2216–26. doi:10.1021/bi9013038.CrossRefPubMed

39.

Feng JG, Liu Q, Qin X, Geng YH, Zheng ST, Liu T, et al. Clinicopathological pattern and Annexin A2 and Cdc42 status in patients presenting with differentiation and lymphnode metastasis of esophageal squamous cell carcinomas. Mol Biol Rep. 2012;39(2):1267–74. doi:10.1007/s11033-011-0859-2.CrossRefPubMed

40.

Diaz VM, Hurtado M, Thomson TM, Reventos J, Paciucci R. Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro. Gut. 2004;53(7):993–1000.CrossRefPubMedPubMedCentral

41.

Brownstein C, Deora AB, Jacovina AT, Weintraub R, Gertler M, Khan KM, et al. Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: enhanced expression by macrophages. Blood. 2004;103(1):317–24. doi:10.1182/blood-2003-04-1304.CrossRefPubMed

42.

Kassam G, Le BH, Choi KS, Kang HM, Fitzpatrick SL, Louie P, et al. The p11 subunit of the annexin II tetramer plays a key role in the stimulation of t-PA-dependent plasminogen activation. Biochemistry. 1998;37(48):16958–66. doi:10.1021/bi981713l.CrossRefPubMed

43.

Huang L, Xu J, Wood DJ, Zheng MH. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. Am J Pathol. 2000;156(3):761–7.CrossRefPubMedPubMedCentral

44.

Forsyth RG, De Boeck G, Baelde JJ, Taminiau AH, Uyttendaele D, Roels H, et al. CD33+ CD14- phenotype is characteristic of multinuclear osteoclast-like cells in giant cell tumor of bone. J Bone Miner Res : Off J Am Soc Bone Miner Res. 2009;24(1):70–7. doi:10.1359/jbmr.080905.CrossRef

Title: Biological characteristics of a novel giant cell tumor cell line derived from spine
Authors: Zhenhua Zhou
Yan Li
Leqin Xu
Xudong Wang
Su Chen
Cheng Yang
Jianru Xiao
Publication date: 01-07-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 7/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-016-4867-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2016

Evaluation of 188Re-labeled NGR–VEGI protein for radioimaging and radiotherapy in mice bearing human fibrosarcoma HT-1080 xenografts

Investigation of FIH-1 and SOCS3 expression in KRAS mutant and wild-type patients with colorectal cancer

Pretreatment lymphocyte to monocyte ratio as a predictor of prognosis in patients with early-stage triple-negative breast cancer

miR-488 acts as a tumor suppressor gene in gastric cancer

Inhibition of miR-15b decreases cell migration and metastasis in colorectal cancer

DLX4 hypermethylation is a prognostically adverse indicator in de novo acute myeloid leukemia

Keynote webinar | Spotlight on antibody–drug conjugates in cancer